調査レポートカテゴリー： visiongain, 世界, 医療/バイオ

Checkpoint Inhibitors for Treating Cancer: Market Report with Forecasts 2016-2026

がん治療用チェックポイント阻害薬の世界市場：CTLA-4阻害薬、PD-1阻害薬

◆タイトル：Checkpoint Inhibitors for Treating Cancer: Market Report with Forecasts 2016-2026
◆商品コード：VGAIN5122113
◆調査・発行会社：visiongain
◆発行日：2015年12月
◆ページ数：136
◆レポート形式：PDF / 英語
◆納品方法：Eメール
◆調査対象地域：グローバル
◆産業分野：製薬・医療
◆販売価格オプション（消費税別）
Single UserGBP1,799 ⇒換算￥260,855見積依頼/購入/質問フォーム
Five UserGBP2,999 ⇒換算￥434,855見積依頼/購入/質問フォーム
Site License（全社内共有可）GBP4,999 ⇒換算￥724,855見積依頼/購入/質問フォーム
※Single UserとDept Licence(Five User)の場合、DRM（デジタル著作権管理）付PDFファイルです。認証されたPC上のみでの閲覧と、PDF閲覧期限は購入日より1年となります。Dept Licence(Five User)は印刷できますが、Single Userは印刷できません。Site Licence/Global Site Licenseの場合は、閲覧・印刷制限はありません。
※販売価格オプションの説明はこちらで、ご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額（日本円）＋消費税＋配送料（Eメール納品は無料）」です。
※Eメールによる納品の場合、通常ご注文当日～2日以内に納品致します。
※商品の納品後、納品日＋5日以内に請求書を発行し、お客様宛に郵送いたしますので、請求書発行日より2ヶ月以内に銀行振込にて支払をお願いします。（振込先：三菱東京UFJ銀行/京橋支店/H&Iグローバルリサーチ株式会社）
※上記の日本語題名はH&Iグローバルリサーチが翻訳したものです。英語版原本には日本語表記はありません。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はvisiongainの日本における正規販売代理店です。

 【レポートの概要】

当調査レポートでは、がん治療用チェックポイント阻害薬の世界市場について調査・分析し、以下の構成でお届けいたします。

・レポートの概要
・イントロダクション
・主要なチェックポイント阻害薬、主要企業分析
・がん治療用チェックポイント阻害薬の世界市場、市場規模
・がん治療用チェックポイント阻害薬の世界市場：地域別市場分析、市場規模予測
・がん治療用チェックポイント阻害薬の世界市場：パイプライン分析
・がん治療用チェックポイント阻害薬の世界市場：定性分析
・専門家の見解
・結論

Checkpoint Inhibitors for Cancer – Explore Sales Potentials of that Rising Market
Are you interested in the future of cancer drugs? Our new analysis forecasts revenues for checkpoint inhibitors. Visiongain’s report gives those predictions to 2026 at overall world market, submarket, product and national level.

Avoid falling behind in data or losing influence. Instead discover what progress, opportunities and revenues those emerging cancer therapies can achieve. There you also explore trends, results, R&D and opportunities, seeing commercial prospects.

Read on, please, to explore the industry for checkpoint inhibitor cancer therapies and see what future revenue that expanding pharmaceuticals market could generate.

Predictions and other analysis to benefit your research, assessments, plans and decisions
The future looks promising for checkpoint inhibitors. New products enter that market and drug candidates reach clinical trials. Discover, from 2016, what revenues and other progress are possible in that emerging, expanding market.

Besides sales forecasting to 2026, our work shows recent results, growth rates and market shares. There you find original analysis. Also assess research and development. You gain 61 tables, 34 charts and two interviews with companies.

Our study’s purpose is to help your research, analyses and decisions on cancer therapies using that emerging drug class. Our work also benefits your authority and reputation for commercial insight, helping you compete and succeed.

The following sections show how our new investigation benefits your work.

Forecasts covering the overall world market and segments for checkpoint inhibitors
Discover in our new analysis revenue predictions to 2026 for checkpoint inhibitor submarkets at overall world level, for cancer therapy, and by therapeutic class:
• CTLA-4 Inhibitors
• PD-1 Inhibitors
• Products in development – the R&D pipeline.

Where lie the best prospects? You assess outlooks for revenue expansion, seeing where you can gain. You also investigate competitors’ actions and outlooks.

That way you hear where needs and business opportunities exist. With a rising incidence of cancers, the demand for better treatment rises, giving pharma companies vast opportunities.

Discover what is possible. You also find sales forecasts by individual drug.

Predictions of products’ sales – what is possible for those cancer-treating drugs?
How will checkpoint inhibitor medicines perform from 2015 to 2026 at world level? Our study forecasts revenues of these brands:
• Yervoy (ipilimumab)
• Opdivo (nivolumab)
• Keytruda (pembrolizumab).

There you find how products can compete and succeed. That way you investigate trends, exploring challenges, changes and opportunities.

Discover what the future holds for checkpoint inhibitors and their developers, producers and marketers. Our work also shows you geographical sales predictions.

National markets – what outlooks for those anticancer drug revenues?
Advances in biopharma expand the range and use of checkpoint inhibitors. Our study shows you individual revenue forecasts to 2026 for seven national and two regional markets:
• United States
• Japan
• Germany, France, United Kingdom, Italy and Spain (EU5)
• European Union market overall
• APAC region, grouped prediction

That way you assess countries and regions with highest revenues and potential sales growth. See what is possible in developed and developing countries.

Our study also explores developments for novel and improved cancer treatments.

R&D for those anticancer medicines – trends, innovations and progress
Our work assesses checkpoint inhibitor R&D in oncology. Profiles appear for 19 drug candidates, with revenue forecasts to 2026 for four agents:
• Atezolizumab (MPDL3280A, Roche)
• Durvalumab (MEDI4736, AstraZeneca/MedImmune)
• Avelumab (MSB0010718C, Merck KGaA/Pfizer)
• Tremelimumab (CP-675,206, AstraZeneca).

That way you examine technological advances, seeing progress in clinical trials.

Our report’s author said: “We expect that market to continue its rise, changing cancer therapy. Those drugs have already made strides in melanoma and NSCLC (non-small cell lung cancer) treatment.

“Checkpoint inhibitors harness the body’s immune system to attack cancerous cells, also using immune memory cells to eliminate relapses.”

Discover in our investigation what is possible. That R&D gains momentum from rising cancer prevalence and other forces raising demand for those emerging therapies.

Events and changes affecting companies treating cancer via checkpoint inhibitors
Explore other issues, including these forces shaping that industry and market:
• Mechanisms and advantages of checkpoint inhibition
• Pricing of treatments and effects of those costs on healthcare payers
• Side effects and regulatory issues, including disadvantages of the therapies
• Biomarkers paving the way for optimum utility
• LAG-3 inhibitors – an emerging field of checkpoint inhibitor research
• Combination therapies – their benefits and promise
• Competition – see how crowded that market could become.

【レポートの目次】

1. Report Overview
1.1 Global Overview of the Checkpoint Inhibitor Anti-Cancer Treatment Market 2015
1.2 Benefits of This Report
1.3 How This Report Delivers
1.4 Key Questions Answered by This Analytical Report
1.5 Who is This Report For?
1.6 Methods of the Study
1.7 Frequently Asked Questions (FAQ)
1.8 Associated Visiongain Reports
1.9 About Visiongain

2. Introduction to the Checkpoint Inhibitor Anti-Cancer World Market 2015
2.1 Checkpoint Inhibitors: A New Era in Immunotherapy
2.2 Checkpoint Inhibitor Drug Treatments in Oncology

3. Leading Checkpoint Inhibitors: Anti-Cancer Drug Forecasts 2016-2026 and Leading Companies in the World Market
3.1 Leading Checkpoint Inhibitor Anti-Cancer Drug Treatments on the Market in 2015
3.1.1 Yervoy (ipilimumab) – Bristol-Myers Squibb
3.1.1.1 Yervoy: Sales Analysis
3.1.2 Opdivo (nivolumab) – Bristol-Myers Squibb/Ono Pharmaceutical
3.1.2.1 Opdivo: Sales Analysis
3.1.3 Keytruda (pembrolizumab) – Merck & Co.
3.1.3.1 Keytruda: Sales Analysis
3.2 Leading Companies in the Checkpoint Inhibitor Anti-Cancer Treatment Market in 2015
3.2.1 Bristol-Myers Squibb Leads the Market

4. Checkpoint Inhibitor Anti-Cancer Treatment: World Market 2016-2026
4.1 The Global Market for Checkpoint Inhibitor Anti-Cancer Treatments in 2014
4.2 The World Anti-Cancer Checkpoint Inhibitor Market: Revenue Forecasts 2015-2026
4.3 Leading Checkpoint Inhibitor Treatment Submarkets Forecast 2016-2026
4.3.1 The CTLA-4 Inhibitors Submarket Forecast 2016-2026
4.3.2 The PD-1 Inhibitors Submarket Forecast 2016-2026
4.3.3 Changing Market Shares: PD-1 Inhibitors Will Lead the Market
4.3.4 Drivers and Restraints of the Checkpoint Inhibitor Anti-Cancer Treatment Market 2016-2026
4.3.4.1 Drivers of the Checkpoint Inhibitor Anti-Cancer Treatment Market
4.3.4.2 Restraints of the Checkpoint Inhibitor Anti-Cancer Treatment Market

5. Leading National Markets for the Checkpoint Inhibitor Anti-Cancer Treatment Market 2016-2026
5.1 Regional Breakdown of the World Checkpoint Inhibitor Anti-Cancer Treatments Market 2014-2015
5.2 World Checkpoint Inhibitor Anti-Cancer Treatment Market: Regional Forecast 2016-2026
5.2.1 How Will Regional Market Shares Change to 2026?
5.3 The US Checkpoint Inhibitor Anti-Cancer Treatment Market Forecast 2016-2026
5.4 The EU Checkpoint Inhibitor Anti-Cancer Treatment Market Forecast 2016-2026
5.4.1 Germany: The Checkpoint Inhibitor Anti-Cancer Treatment Market Forecast 2016-2026
5.4.2 France: The Checkpoint Inhibitor Anti-Cancer Treatment Market Forecast 2016-2026
5.4.3 Italy: The Checkpoint Inhibitor Anti-Cancer Treatment Market Forecast 2016-2026
5.4.4 The UK: The Checkpoint Inhibitor Anti-Cancer Treatment Market Forecast 2016-2026
5.4.5 Spain: The Checkpoint Inhibitor Anti-Cancer Treatment Market Forecast 2016-2026
5.5 Japan: The Checkpoint Inhibitor Anti-Cancer Treatment Market Forecast 2016-2026
5.6 The APAC Market: Checkpoint Inhibitor Anti-Cancer Treatment Market Forecast 2016-2026

6. The Checkpoint Inhibitor Anti-Cancer Treatment Market Pipeline Analysis 2016-2026
6.1 Anti-PD-1 Inhibitors and Anti-PD-L1 Inhibitors
6.1.1 Atezolizumab (MPDL3280A/RG7446) – Roche/Genentech
6.1.2 Durvalumab (MEDI4736) – AstraZeneca/MedImmune
6.1.3 Avelumab – (MSB0010718C) – Merck KGaA/Pfizer
6.1.4 Pidilizumab (CT-011) – CureTech Ltd
6.1.5 AMP-224 – GSK/Amplimmune
6.1.6 TSR-042 – TESARO Bio/AnaptysBio
6.1.7 AMP-514 (MEDI0680) – AstraZeneca/MedImmune
6.1.8 REGN2810 – Regeneron/Sanofi
6.2 CTLA-4 Inhibitors
6.2.1 Tremelimumab (CP-675,206) – AstraZeneca
6.3 LAG-3 (lymphocyte activation gene-3) Inhibitors
6.3.1 IMP321- Prima Biomed
6.3.2 BMS-986016 – Bristol-Myers Squibb
6.3.3 IMP701 – Prima BioMed/Novartis
6.4 KIR Inhibitors
6.4.1 Lirilumab (IPH2102/BMS-986015) – Innate Pharma/Bristol-Myers Squibb
6.5 Anti-NKG2A Inhibitors
6.5.1 IPH2201 – Innate Pharma/AstraZeneca/MedImmune
6.6 Other Checkpoint Inhibitors
6.6.1 VISTA Inhibitors
6.6.1.1 CA-170 – Curis/Aurigene
6.6.2 IDO and TDO Inhibitors
6.6.2.1 Indoximod (NLG-9189) – NewLink Genetics
6.6.2.2 NLG919 – NewLink Genetics
6.6.2.3 INCB024360 – Incyte/Roche
6.6.3 A2aR Inhibitors
6.6.3.1 HTL-1071 – AstraZeneca/Heptares
6.6.4 Future Areas of Pipeline Research

7. Qualitative Analysis of the Checkpoint Inhibitor Anti-Cancer Treatment Market 2016-2026
7.1 SWOT Analysis of the Checkpoint Inhibitor Anti-Cancer Treatment Market 2016-2026
7.2 Strengths and Weaknesses of the Checkpoint Inhibitor Anti-Cancer Treatment Market
7.2.1 A Novel Treatment Method that Harnesses the Immune System’s Vast Potential
7.2.2 Pricing of the Treatments Will Attract Companies
7.2.3 Cost of Treatment Will Restrain Market Access
7.2.4 Side Effects May Prohibit Growth
7.3 Opportunities and Threats for the Checkpoint Inhibitor Anti-Cancer Treatment Market
7.3.1 Biomarkers Pave the Way for Optimum Utility
7.3.2 Combination Therapies Are Achieving Superior Results
7.3.3 The Cost Burden of Expensive Drug Treatments on Healthcare Systems
7.3.4 Crowding of the Market With Similar Products

8. Research Interviews
8.1 Interview with Dr Nicolai Wagtmann, PhD, Chief Scientific Officer, Innate Pharma, Marseille, France
8.1.1 Innate Pharma’s Immunotherapy Portfolio
8.1.2 The Advantages and Mechanisms Used by Checkpoint Inhibitors
8.1.3 The Disadvantages of Checkpoint Inhibitors
8.2 Interview with Dr. Frédéric Triebel, CFO/CSO of Prima Biomed, Founder of Immutep
8.2.1 LAG-3 Inhibitors: An Upcoming Area of Checkpoint Inhibitor Research
8.2.2 Advantages and Disadvantages of LAG-3 Inhibitors on the Checkpoint Inhibitor Market
8.2.3 The Future Direction of the Checkpoint Inhibitor Market for Prima Biomed

9. Conclusions
9.1 The Global Checkpoint Inhibitor Anti-Cancer Treatment Market: Current World Outlook
9.1.1 Driver for Growth: A Robust and Innovative Pipeline for the Checkpoint Inhibitors Anti-Cancer Treatment Market to 2026
9.2 Leading National Markets for the Checkpoint Inhibitor Anti-Cancer Treatment Market 2016-2026: The US and EU Will Retain Their Lead
9.3 The Future of the Checkpoint Inhibitor Anti-Cancer Treatment Market

List of Tables
Table 2.1 Main Types of Checkpoint Inhibitors in Development, 2015
Table 3.1 Yervoy (Ipilimumab): Historical Sales ($m, AGR%), 2011-2014
Table 3.2 Yervoy Forecast, Revenue ($bn), Annual Growth (%), CAGR (%), 2015-2020
Table 3.3 Yervoy Forecast, Revenue ($bn), Annual Growth (%), CAGR (%), 2021-2026
Table 3.4 Opdivo Forecast, Revenue ($bn), Annual Growth (%), CAGR (%), 2015-2020
Table 3.5 Opdivo Forecast, Revenue ($bn), Annual Growth (%), CAGR (%), 2021-2026
Table 3.6 Keytruda Forecast, Revenue ($bn), Annual Growth (%), CAGR (%), 2015-2020
Table 3.7 Keytruda Forecast, Revenue ($bn), Annual Growth (%), CAGR (%), 2021-2026
Table 3.8 Leading Companies in the Checkpoint Inhibitor Treatment Market: Revenue ($bn), Market Share (%), 2014
Table 3.9 Leading Companies in the Checkpoint Inhibitor Treatment Market: Revenue ($bn), Market Share (%), 2015
Table 4.1 Global Market for Anti-Cancer Checkpoint Inhibitors: Revenues ($bn) and Market Shares (%) by Class, 2014
Table 4.2 Checkpoint Inhibitors by Revenue ($bn), 2014
Table 4.3 Checkpoint Inhibitors by Revenue ($bn), 2015
Table 4.4 Global Market Forecast for Anti-Cancer Checkpoint Inhibitors by Class: Market Sizes ($bn), Annual Growth Rates (%), CAGR (%), 2015-2020
Table 4.5 Global Market Forecast for Anti-Cancer Checkpoint Inhibitors by Class: Market Sizes ($bn), Annual Growth Rates (%), CAGR (%), 2021-2026
Table 4.6 Global Market for Anti-Cancer Checkpoint Inhibitors: Revenues ($bn) and Market Shares (%) by Class, 2015
Table 4.7 Global Market Forecast for CTLA-4 Inhibitors: Revenue ($bn), Annual Growth Rate (%), CAGR (%), 2015-2020
Table 4.8 Global Market Forecast for CTLA-4 Inhibitors: Revenue ($bn), Annual Growth Rate (%), CAGR (%), 2021-2026
Table 4.9 Global Market Forecast for PD-1 Inhibitors: Revenue ($bn), Annual Growth Rate (%), CAGR (%), 2015-2020
Table 4.10 Global Market Forecast for PD-1 Inhibitors: Revenue ($bn), Annual Growth Rate (%), CAGR (%), 2021-2026
Table 4.11 Global Market Forecast for Anti-Cancer Checkpoint Inhibitors by Class: Market Shares (%), 2015-2020
Table 4.12 Global Market Forecast for Anti-Cancer Checkpoint Inhibitors by Class: Market Shares (%), 2021-2026
Table 4.13 Drivers and Restraints of the Checkpoint Inhibitor Anti-Cancer Treatment Market, 2015-2026
Table 5.1 Regional and National Breakdown of the Checkpoint Inhibitor Cancer Treatment Market: Market Sizes ($bn), Market Shares (%), 2014
Table 5.2 Forecast of Regional and National Checkpoint Inhibitor Cancer Treatment Markets: Market Sizes ($bn), Annual Growth (%), CAGRs (%), 2015-2020
Table 5.3 Forecast of Regional and National Checkpoint Inhibitor Cancer Treatment Markets: Market Sizes ($bn), Annual Growth (%), CAGRs (%), 2021-2026
Table 5.4 Forecast of Regional and National Checkpoint Inhibitor Cancer Treatment Markets: Market Shares (%), 2014-2019
Table 5.5 Forecast of Regional and National Checkpoint Inhibitor Cancer Treatment Markets: Market Shares (%), 2020-2026
Table 5.6 Forecast of the US Checkpoint Inhibitor Cancer Treatment Market: Market Size ($bn), Annual Growth (%), CAGR (%), 2015-2020
Table 5.7 Forecast of the US Checkpoint Inhibitor Cancer Treatment Market: Market Size ($bn), Annual Growth (%), CAGR (%), 2021-2026
Table 5.8 EU5 Market Shares (%), 2014-2019
Table 5.9 EU5 Market Shares (%), 2020-2026
Table 5.10 Forecast of the EU Checkpoint Inhibitor Cancer Treatment Market: Market Size ($bn), Annual Growth (%), CAGR (%), 2015-2020
Table 5.11 Forecast of the EU Checkpoint Inhibitor Cancer Treatment Market: Market Size ($bn), Annual Growth (%), CAGR (%), 2021-2026
Table 5.12 Forecast of the German Checkpoint Inhibitor Cancer Treatment Market: Market Size ($bn), Annual Growth (%), CAGR (%), 2015-2020
Table 5.13 Forecast of the German Checkpoint Inhibitor Cancer Treatment Market: Market Size ($bn), Annual Growth (%), CAGR (%), 2021-2026
Table 5.14 Forecast of the French Checkpoint Inhibitor Cancer Treatment Market: Market Size ($bn), Annual Growth (%), CAGR (%), 2015-2020
Table 5.15 Forecast of the French Checkpoint Inhibitor Cancer Treatment Market: Market Size ($bn), Annual Growth (%), CAGR (%), 2021-2026
Table 5.16 Forecast of the Italian Checkpoint Inhibitor Cancer Treatment Market: Market Size ($bn), Annual Growth (%), CAGR (%), 2015-2020
Table 5.17 Forecast of the Italian Checkpoint Inhibitor Cancer Treatment Market: Market Size ($bn), Annual Growth (%), CAGR (%), 2021-2026
Table 5.18 Forecast of the UK Checkpoint Inhibitor Cancer Treatment Market: Market Size ($bn), Annual Growth (%), CAGR (%), 2015-2020
Table 5.19 Forecast of the UK Checkpoint Inhibitor Cancer Treatment Market: Market Size ($bn), Annual Growth (%), CAGR (%), 2021-2026
Table 5.20 Forecast of the Spanish Checkpoint Inhibitor Cancer Treatment Market: Market Size ($bn), Annual Growth (%), CAGR (%), 2015-2020
Table 5.21 Forecast of the Spanish Checkpoint Inhibitor Cancer Treatment Market: Market Size ($bn), Annual Growth (%), CAGR (%), 2021-2026
Table 5.22 Forecast of the Japanese Checkpoint Inhibitor Cancer Treatment Market: Market Size ($bn), Annual Growth (%), CAGR (%), 2015-2020
Table 5.23 Forecast of the Japanese Checkpoint Inhibitor Cancer Treatment Market: Market Size ($bn), Annual Growth (%), CAGR (%), 2015-2020
Table 5.24 Forecast of the APAC Checkpoint Inhibitor Cancer Treatment Market: Market Size ($bn), Annual Growth (%), CAGR (%), 2015-2020
Table 5.25 Forecast of the APAC Checkpoint Inhibitor Cancer Treatment Market: Market Size ($bn), Annual Growth (%), CAGR (%), 2021-2026
Table 6.1 Selected Combination Therapies for Atezolizumab, 2015
Table 6.2 Atezolizumab Forecast: Revenue ($bn), 2016-2020
Table 6.3 Atezolizumab Forecast: Revenue ($bn), 2021-2026
Table 6.4 Durvalumab Forecast: Revenue ($bn), 2016-2020
Table 6.5 Durvalumab Forecast: Revenue ($bn), 2021-2026
Table 6.6 Avelumab Forecast: Revenue ($bn), 2017-2020
Table 6.7 Avelumab Forecast: Revenue ($bn), 2021-2026
Table 6.8 Tremelimumab Forecast: Revenue ($bn), 2016-2020
Table 6.9 Tremelimumab Forecast: Revenue ($bn), 2021-2026
Table 7.1 Strengths and Weaknesses of the Checkpoint Inhibitor Cancer Treatment Market, 2015
Table 7.2 Opportunities and Threats of the Checkpoint Inhibitor Cancer Treatment Market, 2015
Table 9.1 Checkpoint Inhibitor Anti-Cancer Treatment Market Forecast by Region: Market Size ($bn), Market Share (%), CAGR (%), 2014, 2016, 2020, and 2026
Table 9.2 Checkpoint Inhibitor Anti-Cancer Treatment Drugs Market Forecasts by Class: Market Size ($bn), Market Share (%), CAGR (%), 2014, 2016, 2020, and 2026

List of Figures
Figure 1.1 Global Checkpoint Inhibitor Anti-Cancer Treatment Market Segmentation Overview, 2015
Figure 3.1 Yervoy (ipilimumab): Historical Sales ($m, AGR%), 2011-2014
Figure 3.2 Yervoy Forecast, Revenue ($bn), 2015-2026
Figure 3.3 Opdivo Forecast, Revenue ($bn), 2015-2026
Figure 3.4 Keytruda Forecast, Revenue ($bn), 2015-2026
Figure 3.5 Leading Companies in the Checkpoint Inhibitor Anti-Cancer Market by Revenue: Market Shares, 2014
Figure 3.6 Leading Companies in the Checkpoint Inhibitor Anti-Cancer Market by Revenue: Market Shares, 2015
Figure 4.1 Global Market for Anti-Cancer Checkpoint Inhibitors: Market Shares by Class (%), 2014
Figure 4.2 Global Market Forecast for Anti-Cancer Checkpoint Inhibitors by Class: Market Sizes ($bn), 2015-2026
Figure 4.3 Global Market for Anti-Cancer Checkpoint Inhibitors: Market Shares by Class (%), 2015
Figure 4.4 Global Market Forecast for CTLA-4 Inhibitors: Revenue ($bn), 2015-2026
Figure 4.5 Global Market Forecast for PD-1 Inhibitors: Revenue ($bn), 2015-2026
Figure 4.6 Global Market for Anti-Cancer Checkpoint Inhibitors: Market Shares by Class (%), 2020
Figure 4.7 Global Market for Anti-Cancer Checkpoint Inhibitors: Market Shares by Class (%), 2026
Figure 5.1 Regional and National Breakdown of the Checkpoint Inhibitor Cancer Treatment Market: Market Shares (%), 2014
Figure 5.2 Forecast of Regional and National Checkpoint Inhibitor Cancer Treatment Markets: Market Sizes ($bn), 2014-2025
Figure 5.3 Forecast of Regional and National Checkpoint Inhibitor Cancer Treatment Markets: Market Shares (%), 2020
Figure 5.4 Forecast of Regional and National Checkpoint Inhibitor Cancer Treatment Markets: Market Shares (%), 2026
Figure 5.5 Forecast of the US Checkpoint Inhibitor Cancer Treatment Market: Market Size ($bn), 2015-2026
Figure 5.6 EU Market for the Checkpoint Inhibitor Cancer Treatment by Leading Country (%), 2014
Figure 5.7 Forecast of the EU Checkpoint Inhibitor Cancer Treatment Market, Market Sizes ($bn), 2014-2025
Figure 5.8 Forecast of the German Checkpoint Inhibitor Cancer Treatment Market: Market Size ($bn), 2015-2026
Figure 5.9 Forecast of the French Checkpoint Inhibitor Cancer Treatment Market: Market Size ($bn), 2015-2026
Figure 5.10 Forecast of the Italian Checkpoint Inhibitor Cancer Treatment Market: Market Size ($bn), 2015-2026
Figure 5.11 Forecast of the UK Checkpoint Inhibitor Cancer Treatment Market: Market Size ($bn), 2015-2026
Figure 5.12 Forecast of the Spanish Checkpoint Inhibitor Cancer Treatment Market: Market Size ($bn), 2015-2026
Figure 5.13 Forecast of the Japanese Checkpoint Inhibitor Cancer Treatment Market: Market Size ($bn), 2015-2026
Figure 5.14 Forecast of the APAC Checkpoint Inhibitor Cancer Treatment Market: Market Size ($bn), 2015-2026
Figure 6.1 Atezolizumab Forecast: Revenue ($bn), 2016-2026
Figure 6.2 Durvalumab Forecast: Revenue ($bn), 2016-2026
Figure 6.3 Avelumab Forecast: Revenue ($bn), 2017-2026
Figure 6.4 Tremelimumab Forecast: Revenue ($bn), 2016-2026
Figure 9.1 Checkpoint Inhibitor Anti-Cancer Drug Treatment Market Forecast by Class: Market Sizes ($bn), 2014, 2016, 2020, and 2026
Figure 9.2 Checkpoint Inhibitor Anti-Cancer Treatment Market Forecasts by Region: Market Size ($bn), 2014, 2016, 2020, and 2026

【レポートのキーワード】

がん治療、チェックポイント阻害薬、CTLA-4阻害薬、PD-1阻害薬

★調査レポート[がん治療用チェックポイント阻害薬の世界市場：CTLA-4阻害薬、PD-1阻害薬] ( Checkpoint Inhibitors for Treating Cancer: Market Report with Forecasts 2016-2026 / VGAIN5122113) 販売に関する免責事項
[がん治療用チェックポイント阻害薬の世界市場：CTLA-4阻害薬、PD-1阻害薬] ( Checkpoint Inhibitors for Treating Cancer: Market Report with Forecasts 2016-2026 / VGAIN5122113) についてEメールでお問い合わせ
◆関連調査資料◆
  • がん治療用チェックポイント阻害薬の世界市場2017-2027
    VGAIN712016 / visiongain / 2017年10月 / visiongain社が発行した当調査レポートでは、がん治療用チェックポイント阻害薬の世界市場について調査・分析し、がん治療用チェックポイント阻害薬の世界市場規模、市場動向、市場予測、関連企業情報などを含め、以下の構成でお届けいたします。 ・レポートの概要 ・イントロダクション ・がん治療用チェックポイント阻害薬の世界市場 　（市場規模予測、市場動向、市場の成長要因・阻害要因など） ・がん治療用チェックポイント阻害薬の世界市場：セグメント別市場分析 ・がん治療用チェックポイント阻害薬の世界市場：地域別市場分析、市場規模予測 ・市場環境分析 ・専門家の見解 ・主要企業分析...Where is the Checkpoint Inhibitors for Treating Cancer market heading? If you are involved in this sector you must read this newly updated report. Visiongain’s report shows you the potential revenues streams to 2027, assessing data, trends, opportunities and business prospects there. Discover how to stay ahead Our 139-page report provides 96 tables, charts, and graphs. Read on to discover the most lucrative areas in the industry and the future market prospects. Our new study lets you assess forecasted sales at overall world market and regional level. See financial results, trends, opportunities, and revenue predictions. Much opportunity remains in this...
  • がん治療用キナーゼ阻害剤の世界市場
    VGAIN5081916 / visiongain / 2015年8月 / 当調査レポートでは、がん治療用キナーゼ阻害剤の世界市場について調査・分析し、以下の構成でお届けいたします。 ・レポートの概要 ・イントロダクション ・がん治療用キナーゼ阻害剤の世界市場 　（市場規模予測、市場の成長要因・阻害要因など） ・主要ながん治療用キナーゼ阻害剤 ・地域別市場分析、市場規模予測 ・がん治療用キナーゼ阻害剤研究開発パイプライン ・市場環境分析 ・専門家の見解...Kinase Inhibitors – Benefit Your Influence Now by Discovering Their Sales Potentials Do you want to find sales potentials of protein kinase inhibitors for treating cancer? You can now explore the latest research and development and market predictions. Our new study shows you R&D trends, results, opportunities and multilevel revenue forecasts. Visiongain’s report shows you what is possible for drugs using protein kinase inhibition. That way you assess the future of cancer treatment. Find progress in that rising industry and market, discovering expected progress and sales, including the influence of new products. Avoid missing out. With our research and analysis...
  • 腎臓がん治療の世界市場動向及び予測
    VGAIN5102609 / visiongain / 2015年10月 / 当調査レポートでは、腎臓がん治療の世界市場について調査・分析し、以下の構成でお届けいたします。 ・レポートの概要 ・イントロダクション ・腎臓がん治療の世界市場 　（市場規模予測、市場の成長要因・阻害要因など） ・腎臓がん治療の世界市場：種類別市場分析 ・腎臓がん治療の世界市場：地域別市場分析、市場規模予測 ・研究開発パイプライン分析 ・市場環境分析 ・専門家の見解...Kidney Cancer Therapies – Now Explore Potentials of New Drugs, Industry Changes and Emerging Opportunities Are you interested in the future of renal cancer treatments? Our new study forecasts those pharmaceutical revenues. There you find outlooks for sales growth in that industry. You also explore trends, results, treatments, R&D and opportunities, seeing commercial prospects. Visiongain’s report gives revenue predictions to 2025 at overall world market, submarket, product and national level. Avoid falling behind in data or losing influence. Instead discover, from 2015, what progress, opportunities and sales are possible for those cancer treatments. Read on, then, to explore renal cancer...
  • がん治療薬の世界市場2017-2027
    VGAIN7081119 / visiongain / 2017年9月 / visiongain社が発行した当調査レポートでは、がん治療薬の世界市場について調査・分析し、がん治療薬の世界市場規模、市場動向、市場予測、関連企業情報などを含め、以下の構成でお届けいたします。 ・レポートの概要 ・イントロダクション ・がん治療薬の世界市場 　（市場規模予測、市場動向、市場の成長要因・阻害要因など） ・がん治療薬の世界市場：セグメント別市場分析 ・がん治療薬の世界市場：地域別市場分析、市場規模予測 ・市場環境分析 ・専門家の見解 ・主要企業分析...The world cancer-treating drugs market is expected to grow at a CAGR of 6.6% in the second half of the forecast period. The market reached $102bn in 2016, dominated by the immunotherapy segment which held 44.1% share of the market. How this report will benefit you Read on to discover how you can exploit the future business opportunities emerging in this sector. In this brand new 194-page report you will receive 110 tables and 101 figures – all unavailable elsewhere. The 194-page report provides clear detailed insight into the world cancer-treating drugs market. Discover the key drivers and challenges affecting...
  • 胃がん治療薬の世界市場：研究開発、市場動向、予測
    VGAIN60708 / visiongain / 2016年6月 / 当調査レポートでは、胃がん治療薬の世界市場について調査・分析し、胃がん治療薬の世界市場規模、市場動向、市場予測、関連企業情報などを含め、以下の構成でお届けいたします。 1. レポート概要 2. 胃がん治療の概要 3. 主要な胃がん治療薬 4. 胃がん治療の研究開発パイプライン分析 2016-2026...Gastric Cancer Therapies – What R&D Progress and Future Revenues Are Possible? Are you interested in the gastric cancer drug market’s future? If so, you find that sales forecasting from 2016 in our new report. See there what is possible for those products and companies. You also explore trends, results and R&D, discovering opportunities and prospects. Visiongain’s study gives revenue predictions to 2026 at overall world market, submarket, product and national level. Avoid falling behind in data or losing influence. Instead discover what progress, opportunities and revenues those anticancer drugs for the human digestive tract can achieve. Please read on...
  • 世界の癌治療用キナーゼ阻害剤市場：Brc-Abl阻害剤/EGFR阻害剤/血管新生阻害剤/BRAF・MEK阻害剤/mTOR阻害剤など
    VISG409052 / visiongain / 2014年6月 / ...Kinase inhibitors – a new study showing you trends, R&D and predicted revenues Do you want to find sales potentials of kinase inhibitors? Now get the latest analysis for those cancer treatments. There you explore developments, other trends, results, opportunities and revenue forecasts. Visiongain’s new report shows you what’s possible for drugs using protein kinase inhibition and related technology. There avoid missing out in data. Instead find progress in that industry and market, discovering expected advances and sales. See now how you can gain. You assess trends, technologies and products, benefiting your reputation for technological, medical and commercial insight. Progress...
  • 出血性障害治療の世界市場2017-2027
    VGAIN7081119 / visiongain / 2017年9月 / visiongain社が発行した当調査レポートでは、出血性障害治療の世界市場について調査・分析し、出血性障害治療の世界市場規模、市場動向、市場予測、関連企業情報などを含め、以下の構成でお届けいたします。 ・レポートの概要 ・イントロダクション ・出血性障害治療の世界市場 　（市場規模予測、市場動向、市場の成長要因・阻害要因など） ・出血性障害治療の世界市場：セグメント別市場分析 ・出血性障害治療の世界市場：地域別市場分析、市場規模予測 ・市場環境分析 ・専門家の見解 ・主要企業分析...Bleeding Disorder Treatment – our new study reveals trends, R&D progress, and predicted revenues Where is the Bleeding Disorder Treatment market heading? If you are involved in this sector you must read this newly updated report. Visiongain’s report shows you the potential revenues streams to 2027, assessing data, trends, opportunities and business prospects there. Discover how to stay ahead Our 172-page report provides 153 tables, charts, and graphs. Read on to discover the most lucrative areas in the industry and the future market prospects. Our new study lets you assess forecasted sales at overall world market and regional level. See...
  • がん治療薬の世界市場：企業動向、治療、研究開発、市場予測
    VGAIN5081912 / visiongain / 2015年7月 / 当調査レポートでは、がん治療薬の世界市場について調査・分析し、以下の構成でお届けいたします。 ・レポートの概要 ・イントロダクション ・がん治療薬の世界市場 　（市場規模予測、市場の成長要因・阻害要因など） ・主要な抗癌剤 ・地域別市場分析、市場規模予測 ・がん治療の研究開発パイプライン ・市場環境分析 ・専門家の見解...Cancer Treatments – Your New Guide to that Market, its R&D and Sales Potentials Do you want to assess the future of cancer-treating medicines? Visiongain’s new report gives you revenue predictions for that industry from 2015, helping you stay ahead. There you discover financial data, R&D trends, opportunities, interviews and revenue forecasts. In our analysis you see forecasted sales to 2025 at overall world market, submarket, product and national level. You assess emerging trends, technologies and branded therapies. With our study, benefit your research, analysis, decisions, presentations and influence. Events shaping that crucial pharma industry – cancer remains a top...
  • 世界の抗がん剤市場：治療法、研究開発動向及び市場予測
    VISG409045 / visiongain / 2014年8月 / ...Cancer treatments – here’s your guide to R&D and sales potentials Do you want to assess the future of cancer-treating medicines? Visiongain’s new report gives you revenue predictions for that industry from 2014, helping you stay ahead. You find financial data, R&D trends, opportunities and outlooks for therapy. In that analysis you see forecasted sales to 2024 at overall world market, submarket, product and national level. You also assess emerging trends, technologies, and expected therapies. Events shaping that pharmaceuticals industry – why cancer remains healthcare’s top priority Discover, then, what the future holds for anti-cancer products. And find how patients...
  • コレステロール低下薬の世界市場2017-2027
    VGAIN7081119 / visiongain / 2017年8月 / visiongain社が発行した当調査レポートでは、コレステロール低下薬の世界市場について調査・分析し、コレステロール低下薬の世界市場規模、市場動向、市場予測、関連企業情報などを含め、以下の構成でお届けいたします。 ・レポートの概要 ・イントロダクション ・コレステロール低下薬の世界市場 　（市場規模予測、市場動向、市場の成長要因・阻害要因など） ・コレステロール低下薬の世界市場：セグメント別市場分析 ・コレステロール低下薬の世界市場：地域別市場分析、市場規模予測 ・市場環境分析 ・専門家の見解 ・主要企業分析...The global cholesterol-lowering drugs market is expected to grow at a CAGR of 4.9% in the first half of the forecast period. The market is estimated at $19.2bn in 2017. In the Statins and Fixed-Dose Combinations segment, Crestor was on the lead in 2016 and held a share of 26.7%. How this report will benefit you Read on to discover how you can exploit the future business opportunities emerging in this sector. In this brand new 181-page report you will receive 89 tables and 107 figures – all unavailable elsewhere. The 181-page report provides clear detailed insight into the global...

    • ◆H&Iグローバルリサーチ株式会社のお客様（例）◆